Clinical Trials Logo
NCT number NCT01985126
Study type Interventional
Source Janssen Research & Development, LLC
Contact
Status Active, not recruiting
Phase Phase 2
Start date September 2013
Completion date October 2016

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of 2 daratumumab treatment regimens in participants with multiple myeloma who have received at least 3 prior lines of therapy (including a proteasome inhibitor [PI] and immunomodulatory drug [IMiD]) or are double refractory to a PI and an IMiD.


Clinical Trial Description

This is an open-label (identity of assigned study drug will be known) study of daratumumab for the treatment of participants with multiple myeloma who have received at least 3 prior lines of therapy including a PI and an IMiD or whose disease is double refractory to both a PI and an IMiD. Up to approximately 150 participants are to be enrolled. The study includes screening, treatment, and follow-up phases. Participants will receive daratumumab by intravenous infusion (28-day cycles) until disease progression, unacceptable toxicity, or other protocol-defined reasons. For all study drug administrations, participants will receive pre- and post-infusion medications for the prevention of infusion related reactions. Follow-up will continue until death, loss to follow up, consent withdrawal for study participation, or study end, whichever occurs first. The study will consist of 2 sequential parts (Part 1 and Part 2). The purpose of Part 1 is to select a dose and schedule for Part 2 of the study. Assessment of tumor response and disease progression will be conducted according to IMWG response criteria. Serial pharmacokinetic blood samples and a pharmacogenomic blood sample will be collected. Safety will be monitored throughout the study. At the end of the study, participants who are benefiting from treatment with daratumumab will have the option to continue treatment.


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


See also
Status Clinical Trial Phase
 Not yet recruiting NCT02852837 - Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy Phase 1
 Not yet recruiting NCT02843074 - Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients Phase 2
 Not yet recruiting NCT02863991 - Oral ONC201 in Relapsed/Refractory Multiple Myeloma Phase 2
 Not yet recruiting NCT02786485 - Study of Matched Unrelated Donor T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies After Allogeneic Transplant Phase 1
 Not yet recruiting NCT02811978 - Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma Phase 3
 Recruiting NCT02507479 - Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies Phase 2
 Recruiting NCT02412878 - A Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing (ARROW) Phase 3
 Recruiting NCT02384083 - Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients Phase 1/Phase 2
 Recruiting NCT02506959 - Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma Phase 2
 Recruiting NCT02541383 - A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma Phase 3
 Recruiting NCT02566265 - Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients Phase 2
 Recruiting NCT02575144 - GEM-CLARIDEX: Ld vs BiRd Phase 3
 Recruiting NCT02499081 - UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment Phase 2
 Active, not recruiting NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 0
 Recruiting NCT02186834 - Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma Phase 1/Phase 2
 Recruiting NCT02169791 - Nonmyeloablative Haploidentical Transplant Followed by MLN9708 Phase 2
 Recruiting NCT02206425 - Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients Phase 1/Phase 2
 Completed NCT02160951 - Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies Phase 1
 Recruiting NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
 Recruiting NCT02078518 - Level of Physical Activity and Its Associations With Fatigue and Quality of Life in Multiple Myeloma Survivors N/A